Key Findings
The research team has developed a wrist-worn, hollow microneedle platform capable of quasi-continuous glucose monitoring in interstitial fluid without the use of glucose oxidase. The system utilizes an electrochemical process to create a localized alkaline environment, allowing a nonenzymatic catalyst to function efficiently at a neutral physiological pH of approximately 7.4. The platform has demonstrated rapid fluid extraction in rats and preliminary feasibility in one human participant.
Technical Details
The device consists of two primary modules:
- Fluid-Extraction Module: Employs hollow microneedles and negative pressure to draw interstitial fluid into a detachable sensor cartridge. This design protects skin from direct electrode contact and allows the cartridge to be rinsed and reused.
- Sensing Module: Uses an Au–Pt/Ni foam composite electrode with a three-dimensional porous structure. To initiate sensing, a brief cathodic pulse triggers a hydrogen evolution reaction, consuming protons and generating hydroxide ions locally. This creates a transient alkaline microenvironment required for the Au–Pt/Ni catalyst to oxidize glucose.
The system incorporates an integrated pH feedback mechanism to regulate the hydrogen evolution and glucose oxidation stages. This closed-loop control prevents over-alkalinization and ensures the sensing step occurs under optimal conditions regardless of extraction volumes or glucose concentrations.
Background & Context
Commercial continuous glucose monitors typically rely on glucose oxidase, which is susceptible to degradation caused by heat, time, and pH shifts. While nonenzymatic sensors avoid these stability issues, they generally require alkaline media to perform optimally. Previous attempts to solve this mismatch involved adding external alkaline solutions, which is impractical for wearable applications.
Significance & Outlook
The use of a detachable, regenerable cartridge potentially extends the device’s lifetime compared to single-use enzyme sensors. Furthermore, the wrist-worn form factor aligns with existing consumer smartwatch ecosystems, facilitating easier integration into wearable health technology. The transition from in vitro and rat studies to a human feasibility test marks a step toward clinical translation of enzyme-free glucose sensing.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
